|
|
|
|
|
Desogestrel
drug data and news
Desogestrel drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Desogestrel | ||
| Brand Names/Synonyms | Cerazette; Cyclessa; DESOGESTREL; Desogen; Desogestrel; Desogestrel [Usan:Ban:Inn]; Desogestrelum [Inn-Latin]; HSDB 3593; Kariva; Mircette; ORG 2969; Org-2969, Cerazette; Ortho-Cept | ||
| Indication | For the prevention of pregnancy in women who elect to use this product as a method of contraception. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Desogestrel is used as a female contraceptive. Desogestrel is a progestin or a synthetic form of the naturally occurring female sex hormone, progesterone. In a woman's normal menstrual cycle, an egg matures and is released from the ovaries (ovulation). The ovary then produces progesterone, preventing the release of further eggs and priming the lining of the womb for a possible pregnancy. If pregnancy occurs, progesterone levels in the body remain high, maintaining the womb lining. If pregnancy does not occur, progesterone levels in the body fall, resulting in a menstrual period. Desogestrel tricks the body processes into thinking that ovulation has already occurred, by maintaining high levels of the synthetic progesterone. This prevents the release of eggs from the ovaries. | ||
| Mechanism Of Action | Binds to the progesterone and estrogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like desogestrel will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge. | ||
| Desogestrel News (When available) |
Ignorance, not faith, behind baby boom Feb 5, 2006 Anti-pregnancy pill making a comeback Feb 2, 2006 Savient Pharmaceuticals, Inc. Announces Exploration of Strategic ... Feb 17, 2006 Savient Pharmaceuticals, Inc. Announces Exploration of Strategic ... Feb 17, 2006 Cytogen and Savient Sign Letter of Intent for Marketing of ... Feb 8, 2006 Anti-pregnancy pill making a comeback Feb 2, 2006 Ignorance, not faith, behind baby boom Feb 5, 2006 Cytogen and Savient Sign Letter of Intent for Marketing of ... Feb 8, 2006 Birth Control Pills Can Cause Blood Clots Jan 30, 2006 Savient Pharmaceuticals Finalizes Agreement for the Settlement of ... Dec 2, 2005 Barr, Organon and Savient Finalize Mircette(R) Settlement and ... Dec 1, 2005 Organon to Settle Mircette Litigation with Duramed Sep 12, 2005 Barr, Organon and Savient Announce Letter of Intent Regarding ... 08 Sep 2005 First line of defence Aug 30, 2005 Watson Pharmaceuticals Receives FDA Approval for Desogestrel and ... Aug 1, 2005 Movers & Shakers EBay, Guidant, Procter & Gamble Aug 1, 2005 EBay, Guidant, Procter & Gamble and more Aug 1, 2005 Oral Contraceptive Shown to Fight Acne Jul 10, 2005 Oral Contraceptive Shown to Fight Acne 11 Jul 2005 Contraception During Perimenopause Jun 22, 2005 Contraception During Perimenopause Jun 22, 2005 Some contraceptive pills also anti-acne Apr 1, 2005 Some contraceptive pills also anti-acne Apr 1, 2005 | ||
| Dosage Forms | TABLET | ||
| Drug_Category | Contraceptives, Oral, Synthetic; ATC:G03AC09 | ||
| Absorption | Following oral administration, the relative bioavailability of desogestrel compared to a solution, as measured by serum levels of etonogestrel, is approximately 100%. | ||
| Interactions |
-->Interactions for Desogestrel: Reduced efficacy and increased incidence of breakthrough bleeding and menstrual irregularities have been associated with concomitant use of rifampin. A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with griseofulvin, ampicillin, and tetracyclines (72). | ||
| Toxicity | Symptoms of overdose include nausea and vaginal bleeding. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,13,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-ol | ||
| Chemical Formula | C22H30O | ||
| Molecular Weight | 310.473 g/mol | ||
| Smiles String | CCC12CC(=C)C3C(C1CCC2(C#C)O)CCC4=CCCCC34 | ||
| Melting Point | 109.5 °C | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 3.718 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Desogestrel is rapidly and completely metabolized by hydroxylation in the intestinal mucosa and on first pass through the liver to etonogestrel. Other metabolites (i.e., 3a-OH-desogestrel, 3b-OH-desogestrel, and 3a-OH-5a-H-desogestrel) with no pharmacologic actions also have been identified and these metabolites may undergo glucuronide and sulfate conjugation. | ||
| Half Life | 27.8±7.2 hours | ||
| Protein Binding [%] | 98.30% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.rxlist.com/cgi/generic/desest.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00762 | ||
| CAS Registry Number | 54024-22-5 | ||
| KEGG Compound ID | C07629 | ||
| PubChem ID | SID:181763 | ||
| PharmGKB ID | PA449238 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2042533 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |